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The rarity of thymic epithelial tumors (TETs) creates unique challenges in conducting translational
research and developing newer paradigms of treatment (1). Nevertheless, steady progress in genome
research, the development of thymic cell lines, and an increase in collaborative efforts between
various institutions have helped in fostering an increase in the understanding of the biology of
TETs and associated paraneoplastic syndromes and given an impetus to the development of newer
treatment options for patients with these rare tumors.
Within the last few years, a number of unique genomic changes have been described in TETs
(2). Thymic carcinomas have been found to frequently harbor mutations in epigenetic regulatory
genes (3). A specific mutation in GTF2I on chromosome 7 is present at a high frequency in World
Health Organization (WHO) subtype A and AB thymomas (4). A nine-gene signature has been
developed to predict the metastatic behavior of thymomas (5). The ongoing study of thymoma as
part of The Cancer Genome Atlas (TCGA) project promises to add significantly to the existing body
of knowledge about genomic alterations in TETs.
The association between thymomas and autoimmune paraneoplastic disorders is well recognized
(6). Some patients with thymoma are alsomore susceptible to infectious complications due to under-
lying immune dysregulation (7). Various pathogenic mechanisms implicated in the development of
immune dysfunction include decreased expression of the autoimmune regulator (AIRE) gene and
the presence of anti-cytokine antibodies (8–13). These discoveries have influenced the screening and
management paradigms for patients with thymoma.
Treatment strategies for newly diagnosed and recurrent TETs have also evolved over time. Surgery
is considered the cornerstone of management of early stage TETs and complete resection of the
tumor has a major impact on prognosis (14). For locally advanced disease, thymectomy with en
bloc removal of all involved structures is indicated (15). Active areas of investigation focusing on the
surgicalmanagement of TETs include an evaluation ofminimally invasive surgery and an assessment
of the role of surgery for recurrent TETs (16–19). Though of unproven benefit and with some
controversy, post-operative radiotherapy is recommended after resection of stage III and IVA TETs,
and can be considered for stage II thymic carcinoma and cases of stage II thymoma at high risk
for recurrence (WHO B3 histology; extensive transcapsular invasion) (15, 20, 21). Chemotherapy
is used for induction therapy in cases of stage III/IVA TETs and for treatment of unresectable and
recurrent disease (15). There is scant evidence to support the use of chemotherapy after resection of
TETs (22).
Contributions to the research topic on “Novel Treatments for Thymoma and Thymic Carcinoma”
highlight recent developments in the understanding of the biology of TETs and review various
aspects of management of TETs. Huang and colleagues describe previously unreported changes in
the expression of apoptosis-related genes in WHO subtype B3 thymomas and thymic squamous
cell carcinomas (23). These changes include up-regulation of the anti-apoptotic gene BIRC-3,
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overexpression of the BIRC-3 protein, and reduced expression
of the pro-apoptotic gene, MTCH2 in thymic squamous cell
carcinomas, and reduced expression of the pro-apoptotic gene,
PMAIP1/NOXA in WHO subtype B3 thymomas. These discov-
eries have potential therapeutic implications since drugs targeting
BIRC-3 and PMAIP-1 are in development (24).
Martinez and Browne review immunological deficiencies asso-
ciated with thymoma and suggest a paradigm for comprehen-
sive immunological evaluation in patients with thymoma, which
should include an assessment of quantitative immunoglobulins,
lymphocyte phenotyping, a vaccine challenge in patients sus-
pected to have antibody deficiency and detection of anti-cytokine
antibodies, whenever possible (25). Possible therapeutic interven-
tions include immunoglobulin replacement in patients experienc-
ing recurrent sinopulmonary infections due to immunoglobulin
deficiency, and use of topical or systemic antifungal drugs in
patients susceptible to chronic mucocutaneous candidiasis due to
the presence of IL-17 or IL-22 antibodies (25).
Shapiro and Korst discuss the role of surgery for thymic
tumors with pleural involvement (26). Surgical approaches that
can be considered in this setting include metastasectomy for
patients with a limited number of pleural lesions and extrapleu-
ral pneumonectomy for patients with more extensive pleural
involvement. Data supporting the potential utility of intraopera-
tive, hyperthermic, intrathoracic chemotherapy are also discussed
and the need for prospective clinical trials to firmly establish
the role of surgery for the management of stage IVA TETs is
highlighted.
The role of radiation therapy in the management of thymic
epithelial tumors is reviewed by Komaki and Gomez (27). The
indications for adjuvant and definitive radiation therapy are dis-
cussed as well as techniques to deliver radiation and the long-term
effects of mediastinal radiation therapy.
Finally, the review by Chen and colleagues focuses on the latest
advances in systemic therapies for TETs (28). Results from clin-
ical trials evaluating novel biological therapies including histone
deacetylase inhibitors, insulin-like growth factor inhibitors, and
multikinase inhibitors are discussed, and ongoing phase II trials
for TETs are highlighted.
The aforementioned manuscripts provide a snapshot of impor-
tant research efforts related to TETs. Continued advances in the
field have resulted in an ever increasing stream of data that offer
newer insights into the biology of these rare tumors and support
the use of newer paradigms of management for patients with
thymoma and thymic carcinoma.
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